FORA Capital LLC Makes New Investment in Intellia Therapeutics, Inc. $NTLA

Key Points

• FORA Capital LLC acquired 23,967 shares of Intellia Therapeutics, valued at approximately $170,000, signaling growing interest from institutional investors.
• Analysts have varied price targets for Intellia Therapeutics, with estimates ranging from $7.00 to $54.00; the stock currently has a consensus target price of $29.05.
• Intellia Therapeutics reported a revenue increase of 104.3% year-over-year, with quarterly revenue of $14.25 million surpassing estimates.

FORA Capital LLC bought a new position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 23,967 shares of the company's stock, valued at approximately $170,000.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Ensign Peak Advisors Inc lifted its position in shares of Intellia Therapeutics by 2.9% during the fourth quarter. Ensign Peak Advisors Inc now owns 39,169 shares of the company's stock worth $457,000 after purchasing an additional 1,100 shares during the last quarter. HighTower Advisors LLC lifted its position in shares of Intellia Therapeutics by 8.2% during the first quarter. HighTower Advisors LLC now owns 16,921 shares of the company's stock worth $120,000 after purchasing an additional 1,282 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in shares of Intellia Therapeutics by 56.4% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 4,590 shares of the company's stock worth $33,000 after purchasing an additional 1,655 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Intellia Therapeutics by 28.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,148 shares of the company's stock worth $95,000 after purchasing an additional 1,808 shares during the last quarter. Finally, GF Fund Management CO. LTD. bought a new stake in shares of Intellia Therapeutics during the fourth quarter worth $25,000. 88.77% of the stock is currently owned by institutional investors.

Intellia Therapeutics Stock Performance

NTLA traded up $0.05 on Tuesday, hitting $11.40. The company had a trading volume of 3,457,498 shares, compared to its average volume of 4,083,261. The stock has a fifty day moving average price of $11.32 and a 200-day moving average price of $9.58. Intellia Therapeutics, Inc. has a 12-month low of $5.90 and a 12-month high of $23.76. The stock has a market capitalization of $1.22 billion, a price-to-earnings ratio of -2.43 and a beta of 2.28.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.99) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.03) by $0.04. Intellia Therapeutics had a negative return on equity of 57.48% and a negative net margin of 908.48%.The company had revenue of $14.25 million for the quarter, compared to analyst estimates of $12.26 million. During the same quarter in the previous year, the firm earned ($1.52) earnings per share. The firm's quarterly revenue was up 104.3% compared to the same quarter last year. Analysts forecast that Intellia Therapeutics, Inc. will post -5.07 EPS for the current fiscal year.

Insider Activity at Intellia Therapeutics

In related news, EVP Edward J. Dulac III sold 7,462 shares of the stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $14.02, for a total value of $104,617.24. Following the transaction, the executive vice president owned 106,062 shares in the company, valued at approximately $1,486,989.24. This represents a 6.57% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director William J. Chase purchased 100,000 shares of the business's stock in a transaction that occurred on Wednesday, August 20th. The stock was acquired at an average price of $10.03 per share, for a total transaction of $1,003,000.00. Following the acquisition, the director owned 134,693 shares in the company, valued at $1,350,970.79. This trade represents a 288.24% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders sold 12,534 shares of company stock worth $153,837. 3.10% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on NTLA. Chardan Capital decreased their price objective on Intellia Therapeutics from $68.00 to $60.00 and set a "buy" rating for the company in a report on Monday, August 11th. Canaccord Genuity Group decreased their price objective on Intellia Therapeutics from $74.00 to $54.00 and set a "buy" rating for the company in a report on Tuesday, June 3rd. Royal Bank Of Canada decreased their price objective on Intellia Therapeutics from $25.00 to $21.00 and set an "outperform" rating for the company in a report on Friday, August 8th. Guggenheim restated a "buy" rating and issued a $14.00 price objective on shares of Intellia Therapeutics in a report on Wednesday, August 13th. Finally, HC Wainwright decreased their price objective on Intellia Therapeutics from $30.00 to $25.00 and set a "buy" rating for the company in a report on Friday, August 8th. Twelve equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Intellia Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $29.05.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.